Skip to main content

Table 1 Baseline characteristics

From: Impact of therapeutic plasmapheresis on the duration of organ failure in patients with hypertriglyceridemia-associated acute pancreatitis

Variable

All n = 122

Medical n = 76

Plasmapheresis n = 46

P value

Age, mean ± SD, y

39.47 ± 9.44

39.28 ± 10.05

39.78 ± 8.42

0.775

Male sex, n (%)

96 (78.7)

61 (80.3)

35 (76.1)

0.585

BMI, mean ± SD, kg/m2

27.73 ± 4.10

28.14 ± 4.30

27.04 ± 3.67

0.152

BMI categories, n (%)

0.155

 18.5–24.9

31 (25.4)

15 (19.7)

16 (34.8)

 

 25.0–29.9

60 (49.2)

39 (51.3)

21 (45.7)

 

  ≥ 30.0

31 (25.4)

22 (28.9)

9 (19.6)

 

 Smoking

48 (39.9)

26 (34.2)

22 (47.8)

0.136

 Alcohol abuse

52 (42.6)

33 (43.4)

19 (41.3)

0.819

Diabetes, n (%)

0.545

 Yes

23 (18.9)

13 (17.1)

10 (21.7)

 

 No

63 (51.6)

38 (50.0)

25 (54.3)

 

 Unknown

36 (29.5)

25 (32.9)

11 (23.9)

 

Time intervala, n (%)

0.099

 24 h

74 (60.7)

45 (59.2)

29 (63.0)

 

 48 h

37 (30.3)

21 (27.6)

16 (34.8)

 

 72 h

11 (9.0)

10 (13.2)

1 (2.2)

 

APACHE II score, median(IQR)

10.00 (6.00–14.00)

8.50 (5.00–13.00)

11.00 (8.00–15.25)

0.012

APACHE II categories,n (%)

0.031

  < 8

41 (33.6)

31 (40.8)

10 (21.7)

 

  ≥ 8

81 (66.4)

45 (59.2)

36 (78.3)

 

 SOFA score, median(IQR)

3.00 (2.00–4.00)

3.00 (2.00–4.00)

3.50 (2.00–5.00)

0.398

Organ failure

 Respiratory, n (%)

99 (81.1)

59 (77.6)

40 (87.0)

0.202

 Cardiovascular, n (%)

11 (9.0)

3 (3.9)

8 (17.4)

0.020

 Renal, n (%)

34 (27.9)

21 (27.6)

13 (28.3)

0.940

 Baseline triglyceride, median(IQR), mmol/L

23.71 (17.50–40.14)

20.87 (16.64–30.60)

30.05 (18.20–61.95)

0.007

  1. BMI body mass index, APACHE II acute physiology and chronic health evaluation II; SOFA sequential organ failure assessment
  2. aTime interval was categorized based on the time from the symptom onset to study enrollment